Pentostatin in the treatment of hairy-cell leukemia

Best Practice and Research: Clinical Haematology

Volumn 16, Issue 1, 2003, Pages 91-99

  Grever, Michael R ^a   Doan, Charles A ^b   Kraut, Eric H ^c  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c Division of Hematology/Oncology   (United States)

Author keywords

2 deoxycoformycin; Adenosine deaminase; Hairy cell leukemia; Nipent; Pentostatin

Indexed keywords

ADENOSINE DEAMINASE; ALPHA INTERFERON; CLADRIBINE; PENTOSTATIN; PURINE NUCLEOSIDE DERIVATIVE; RITUXIMAB;

BONE MARROW HYPOPLASIA; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; ENZYME INHIBITION; FOLLOW UP; HAIRY CELL LEUKEMIA; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; INFECTION; KIDNEY DYSFUNCTION; LYMPHOCYTE FUNCTION; NEPHROTOXICITY; NEUROTOXICITY; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SECOND CANCER; SIDE EFFECT; T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; NEOPLASM; RELAPSE; REMISSION; STANDARDIZATION; SURVIVAL;

EID: 0037251727     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6926(03)00002-1     Document Type: Review

References (27)

1. Bouroncle BA, Wiseman BK & Doan CA. Leukemic reticuloendotheliosis. Blood 1958; 13: 609-630.
2. Quesada JR, Reuben J, Manning JT et al. Alpha interferon for induction of remission in hairy-cell leukemia. New England Journal of Medicine 1984; 310: 15-18.
3. Spiers ASD, Parekh SJ & Bishop MB. Hairy cell leukemia: induction of complete remission with pentostatin (2′-deoxycoformycin). Journal of Clinical Oncology 1984; 2: 1336-1342.
4. Kraut EH, Bouroncle BA & Grever MR. Low-dose deoxycoformycin in the treatment of hairy cell leukemia. Blood 1986; 68: 1119-1122.
5. Piro LD, Carrera CJ, Carson DA et al. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. New England Journal of Medicine 1990; 322: 1117-1121.
6. Johnston JB, Eisenhauer E, Corbett WEW et al. Efficacy of 2′-deoxycoformycin in hairy cell leukemia: a study of the National Cancer Institute of Canada Clinical Trials Group. Journal of the National Cancer Institute 1988; 80: 765-769.
7. Andrey J & Saven A. Therapeutic advances in the treatment of hairy cell leukemia. Leukemia Research 2001; 25: 361-368.
8. Giblett ER, Anderson JE, Cohen F et al. Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972; ii: 1067.
9. Coleman MS, Donofrio J, Hatton JJ et al. Identification and quantitation of adenine deoxynucleotides in erythrocytes of a patient with adenosine deaminase deficiency and severe combined immunodeficiency. Journal of Biological Chemistry 1978; 253: 1619.
10. Cohen A, Hirschhom R, Horowitz SD et al. Deoxyadenosine triphosphates as a potentially toxic metabolite in adenosine deaminase deficiency. Proceedings of the National Academy of Sciences of the USA 1978; 76: 472.
11. Smyth JF, Chassin MM, Harrap KR et al. 2′ deoxycoformycin (DCF): phase I trial and clinical pharmacology. Proceedings of the American Association of Cancer Research 1979; 20: 47.
12. Grever MR, Siaw MF, Jacob WF et al. The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lympho-proliferative malignancy. Blood 1981; 57: 406-417.
13. O'Dwyer PJ, Spiers ASD & Marsoni S. Association of severe and fatal infections and treatment with pentostatin. Cancer Treatment Reports 1986; 70: 1117-1120.
14. Grever MR, Leiby JM, Kraut EH et al. Low-dose deoxycoformycin in lymphoid malignancy. Journal of Clinical Oncology 1985; 3: 1196-1201.
15. Alexander SD, Spiers TD, Moore D et al. Remissions in hairy-cell leukemia with pentostatin (2′-deoxycoformycin). New England Journal of Medicine 1987; 316: 825-830.
16. Kraut EH, Bouroncle BA & Grever MR. Pentostatin in the treatment of advanced hairy cell leukemia. Journal of Clinical Oncology 1989; 7: 168-172.
17. Thaler J, Grunewald K, Gattringer C et al. Long-term follow-up of patients with hairy cell leukemia treated with pentostatin: lymphocyte subpopulations and residual bone marrow infiltration. British Journal of Haematology 1993; 84: 75-82.
18. Dearden CE, Matutes E, Hilditch BL et al. Long-term follow-up of patients with hairy cell leukemia after treatment with pentostatin or cladribine. British Journal of Haematology 1999; 106: 515-519.
19. Ribeiro P, Bouaffia F, Peaud PY et al. Long term outcome of patients with hairy cell leukemia treated with pentostatin. Cancer 1999; 85: 65-71.
20. Rafel M, Cervantes F, Beltran JM et al. Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients. Cancer 2000; 88: 352-357.
21. Johnston JB, Eisenhauer E, Wainman N et al. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study. Seminars in Oncology 2000; 27(2 supplement 5): 32-36.
22. Bouroncle BA. Leukemic reticuloendotheliosis (hairy cell leukemia). Blood 1979; 53: 412-436.
23. Grever MR, Kopecky K, Foucar MK et al. Randomized comparison of pentostatin versus interferon Alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. Journal of Clinical Oncology 1995; 13: 974-982.
24. Habermann TM, Andersen JW, Cassileth PA et al. Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukemia. British Journal of Haematology 1992; 80: 466-471.
25. Flinn IW, Kopecky KJ, Foucar MK et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000; 96: 2981-2986.
26. Hakimian D, Tallman MS, Kiley C et al. Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 1993; 82: 1798-1802.
27. Hagberg H & Lundholm L. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukemia. British Journal of Haematology 2001; 115: 609.